Adaptive Biotechnologies CORP

Adaptive Biotechnologies announced plans for a $250 million convertible senior notes offering and the separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses.

Adaptive Biotechnologies Corporation shareholders approved director elections, executive compensation advisory vote, and ratified the independent auditor at the June 5, 2026 annual meeting.

Adaptive Biotechnologies announced robust first quarter 2026 financial results, driven by significant growth in its Minimal Residual Disease (MRD) business.

Adaptive Biotechnologies reported robust financial results for Q4 and full year 2025, driven by significant revenue growth and a shift to profitability in its MRD business.

Adaptive Biotechnologies announced preliminary, unaudited Q4 and full year 2025 results, showcasing significant revenue and clonoSEQ test volume increases, and outlining a path to company-wide profitability by late 2026.

Adaptive Biotechnologies' 70% owned subsidiary, Digital Biotechnologies, announced an initial closing of its Series A Preferred Stock financing, targeting up to $15 million.

Adaptive Biotechnologies Corporation announced its first quarter 2026 financial results, showcasing a 35% year-over-year revenue increase driven by strong performance in its MRD business.

Adaptive Biotechnologies achieved net income in Q3 2025, driven by strong MRD revenue growth and a one-time revenue recognition from the Genentech collaboration termination.

Adaptive Biotechnologies reported significant revenue growth and reduced net losses in its latest quarterly filing, driven by strong performance in its MRD business and increased clonoSEQ test volumes.

Adaptive Biotechnologies' Q1 2025 shows revenue growth driven by MRD, alongside reduced operating losses.

Adaptive Biotechnologies' Q3 2024 results show revenue growth driven by the MRD segment, despite a decrease in Immune Medicine revenue.

Adaptive Biotechnologies reported a decrease in revenue for the second quarter of 2024, alongside restructuring efforts and impairment charges.

Adaptive Biotechnologies reported significant revenue growth and a substantial reduction in net losses for 2025, driven by its MRD business and strategic partnerships.

Adaptive Biotechnologies' 2024 revenue increased to $179.0 million, driven by a 42% growth in its MRD business, while operating expenses significantly decreased.

Adaptive Biotechnologies saw a revenue decrease in 2023, but also a significant growth in clonoSEQ test volume and progress in its immune medicine pipeline.

Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp, sold 1,299 shares of common stock on July 30, 2026 for $24.00 per share.

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, sold 492,400 shares of common stock on July 21, 2026.

Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp, sold 5,000 shares of common stock on July 16, 2026 for $23.00 per share.

Francis Lo, Chief People Officer of Adaptive Biotechnologies Corp, sold 105,762 shares of common stock on July 15, 2026 for $22.59 per share.

Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp, reported the sale of company stock totaling over 386,000 shares.

Adaptive Biotechnologies Corp. reports significant stock transactions by Chief People Officer Francis Lo, including acquisitions and dispositions under a Rule 10b5-1 trading plan.

Adaptive Biotechnologies Corporation announces its 2026 Annual Meeting of Shareholders to be held virtually on June 5, 2026.

Adaptive Biotechnologies will hold its annual shareholder meeting on June 10, 2025, seeking votes on director election, executive compensation, and auditor ratification.

Adaptive Biotechnologies Corporation invites shareholders to its 2025 Annual Meeting and reports on 2024 corporate performance, including revenue growth in the MRD business and reduced operating expenses.

Adaptive Biotechnologies urges stockholders to re-elect directors Peter Neupert and Michelle Griffin, addressing concerns raised by ISS regarding Dr. Rob Hershberg's board memberships.

Adaptive Biotechnologies Corporation will hold its annual shareholder meeting on June 7, 2024, to vote on director elections, executive compensation, and auditor ratification.

Adaptive Biotechnologies Corporation will hold its 2024 Annual Meeting of Shareholders virtually on June 7, 2024, to vote on director elections, executive compensation, and auditor ratification.

Viking Global Investors filed an amended Schedule 13G to reflect the removal of David C. Ott as a reporting person.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Adaptive Biotechnologies Corp. following an internal realignment.

BlackRock, Inc. reports a 7.9% beneficial ownership stake in Adaptive Biotechnologies Corp, holding 11,992,448 common shares.

Rubric Capital Management LP and David Rosen have reported a 4.12% beneficial ownership stake in Adaptive Biotechnologies Corporation as of June 30, 2025, indicating a passive investment position.

ARK Investment Management LLC and its CEO Catherine D. Wood have filed an amended Schedule 13G, disclosing a beneficial ownership of 2.9% in Adaptive Biotechnologies Corporation's common stock as of May 31, 2025.

ARK Investment Management LLC and its CEO, Catherine D. Wood, have jointly disclosed a beneficial ownership of 5.2% in Adaptive Biotechnologies Corporation, totaling 7,732,570 shares of common stock.